Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. That said, here are three stocks under $50 to swipe left on and some alternatives you should look into instead.
Amphastar Pharmaceuticals (AMPH)
Share Price: $19.60
Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ: AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.
Why Is AMPH Not Exciting?
- Annual revenue growth of 3.2% over the last two years was below our standards for the healthcare sector
- Revenue base of $720.5 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Efficiency has decreased over the last two years as its adjusted operating margin fell by 10.9 percentage points
Amphastar Pharmaceuticals is trading at $19.60 per share, or 7x forward P/E. Check out our free in-depth research report to learn more about why AMPH doesn’t pass our bar.
Antero Resources (AR)
Share Price: $33.36
Holding roughly 521,000 net acres across West Virginia, Ohio, and Pennsylvania, Antero Resources (NYSE: AR) drills and produces natural gas, natural gas liquids, and oil from underground rock formations in the Appalachian Basin.
Why Do We Think Twice About AR?
- 5.6% annual revenue growth over the last five years was slower than its energy upstream and integrated energy peers
- Costs have risen faster than its revenue over the last five years, causing its EBITDA margin to decline by 5.1 percentage points
At $33.36 per share, Antero Resources trades at 8.4x forward P/E. To fully understand why you should be careful with AR, check out our full research report (it’s free).
Calumet (CLMT)
Share Price: $44.18
With roots dating back to 1919 and facilities strategically positioned from Louisiana to Montana, Calumet (NASDAQ: CLMT) refines crude oil into specialty products like lubricating oils, solvents, and waxes used in cosmetics, batteries, and industrial applications.
Why Do We Think CLMT Will Underperform?
- Gross margin of 7.4% reflects its high production costs and unfavorable asset base
- Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
- 7× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings
Calumet’s stock price of $44.18 implies a valuation ratio of 61.2x forward P/E. If you’re considering CLMT for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
